References
- Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet. 2007;369:767–78.
- Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003;48:1093–101.
- Pain CE, McCann U. Challenges in the management of juvenile idiopathic arthritis with etanercept. Biologics. 2009;3:127–39.
- Gerloni V, Pontikaki I, Gattinara M, et al. Efficacy of repeated intravenous infusion of an anti-tumor necrosis factor-a mono-clonal antibody, infliximab, in persistently active refractory juvenile idiopathic arthritis: results of an open-label prospective study. Arthritis Rheum. 2005;52:548–53.
- Lamot L, Bukovac LT, Vidovic M, Frleta M, Hatjacek M. The 'head-to-head' comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis. Clin Exp Rheumatol. 2011;29:131–9.
- Lahdenne P, Vähäsalo P, Honkanen V. Infliximab or etanercept in the treatment of children with refractory juvenile idiopathic arthritis: an open label study. Ann Rheum Dis. 2003;62:245–7.
- Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A. Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum. 2010;62:2517–24.
- Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, with-drawal phase III trial. Lancet. 2008;371:998–1006.
- Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64:699–703.
- Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–85.
- Askling J, Fored CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis. 2005;64:1421–6.
- Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136–45.
- Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of obser-vation. Arthritis Rheum. 2007;56:1433–9.
- Homeff G, Foeldvari I, Minden K, Moebius D, Hospach T. Report on malignancies in the German juvenile idiopathic arthritis registry. Rheumatology (Oxford). 2011;50:230–6.
- Baecklund E, Feltelius N, Klareskog L. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. BMJ. 1998;317:180–1.
- Simard JF, Neovius M, Hagelberg S, Askling J. Juvenile idio-pathic arthritis and risk of cancer: a nationwide cohort study. Arthritis Rheum. 2010;62:3776–82.
- McCroskery P, Wallace CA, Lovell DJ, Stryker S, Chemyukhin N, Blosch C, Zack DJ. Summary of worldwide pediatric malig-nancies reported after exposure to etanercept. Pediatr Rheumatol 2010;8:18. doi:10.1186/1546-0096-8-18.
- Trulson A, Nilsson S, Venge P. Monocyte activation in patients with nonseminomatous germ cell tumour of the testis before and after tumour eradication. J Clin Pathol. 1996;49:381–5.
- Purdue MP, Sakoda LC, Graubard BI, et al. Polymorphisms and risk of testicular germ cell tumors: a case-control investigation of immune function gene. Cancer Epidemiol Biomarkers Prey. 2007;16:77–83.